[68Ga]Ga-P15-041双膦酸盐骨显像剂评估前列腺癌骨转移:[68Ga]Ga-PSMA-11 PET/CT对照研究
一项前瞻性研究纳入35例前列腺癌骨转移患者,1周内均行[68Ga]Ga-P15-041与[68Ga]Ga-PSMA-11 PET/CT。[68Ga]Ga-P15-041检出更多病灶(525 vs 509,P<0.001),平均SUV更高(20.73±14.67 vs 11.13±8.12,P<0.0001),并建立P15-041-RADS将病灶分为5类。
要点
- [68Ga]Ga-P15-041 PET/CT检出病灶数多于[68Ga]Ga-PSMA-11 PET/CT(525 vs 509,P<0.001)。
- 前者平均SUV为20.73±14.67,高于后者的11.13±8.12(P<0.0001)。
- P15-041-RADS将85.71%的PSMA-RADS 3类病灶和95.00%的5T病灶重分类为更高置信度类别。
核心结论
- [68Ga]Ga-P15-041 PET/CT是一种有前景且可及的骨显像剂,可作为[68Ga]Ga-PSMA-11 PET/CT的补充用于前列腺癌骨转移的诊断与分类。
研究设计与样本
- 前瞻性研究纳入35例前列腺癌骨转移患者,均于1周内接受[68Ga]Ga-P15-041与[68Ga]Ga-PSMA-11 PET/CT检查。
- 以[68Ga]Ga-PSMA-11 PET/CT检出的病灶按PSMA-RADS 2.0进行分类。
- 建立P15-041-RADS,依据SUVmax和形态学改变将前列腺癌骨转移分为5类。
主要发现
- [68Ga]Ga-P15-041 PET/CT检出病灶525个,[68Ga]Ga-PSMA-11 PET/CT检出509个(P<0.001)。
- [68Ga]Ga-P15-041平均SUV为20.73±14.67,[68Ga]Ga-PSMA-11为11.13±8.12(P<0.0001)。
- [68Ga]Ga-P15-041检出成骨性病灶504个,[68Ga]Ga-PSMA-11检出391个(P<0.0001)。
- P15-041-RADS将85.71%的PSMA-RADS 3类病灶和95.00%的5T病灶重分类为更高置信度类别。
关键数值与推荐
- P15-041-RADS基于SUVmax和形态学改变将前列腺癌骨转移分为5类。
- P15-041-RADS将85.71%的PSMA-RADS 3类病灶和95.00%的5T病灶重分类为更高置信度类别。
临床怎么用
- 原文结论认为[68Ga]Ga-P15-041 PET/CT有前景且可及,可作为[68Ga]Ga-PSMA-11 PET/CT的补充用于前列腺癌骨转移的诊断与分类。
局限性
- 样本量小。
- 缺乏病理学金标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Accurate diagnosis of bone metastases in prostate cancer is essential for staging, prognosis, and treatment. Although PSMA PET/CT is highly effective, complementary imaging is needed to clarify indeterminate lesions. The novel bisphosphonate-based agent [68Ga]Ga-P15-041 shows superior diagnostic accuracy over conventional SPECT imaging, indicating its potential as an auxiliary diagnostic tool. This study explores its role in detecting and assessing prostate cancer bone metastases. PATIENTS AND METHODS: This prospective study enrolled 35 patients with prostate cancer and skeletal metastases, who underwent both [68Ga]Ga-P15-041 and [68Ga]Ga-PSMA-11 PET/CT within 1 week. Lesions detected by [68Ga]Ga-PSMA-11 PET/CT were classified using Prostate-specific Membrane Antigen Reporting and Data System 2.0. RESULTS: [68Ga]Ga-P15-041 PET/CT detected more lesions than [68Ga]Ga-PSMA-11 PET/CT (525 vs 509, P < 0.001) and demonstrated significantly higher tracer uptake, with a mean SUV of 20.73 ± 14.67 compared with 11.13 ± 8.12 (P < 0.0001). It detected significantly more osteoblastic lesions (504 vs 391, P < 0.0001). In addition, this study established the Reporting and Data System for [68Ga]Ga-P15-041 (P15-041-RADS), which classifies prostate cancer bone metastases into 5 categories based on SUVmax and morphologic changes. P15-041-RADS reclassified 85.71% of Prostate-specific Membrane Antigen Reporting and Data System category 3 lesions and 95.00% of 5T lesions into higher-confidence categories, offering improved diagnostic clarity. Limitations include small sample size and lack of pathologic gold standards. CONCLUSIONS: [68Ga]Ga-P15-041 PET/CT is a promising and accessible bone imaging agent that could complement [68Ga]Ga-PSMA-11 PET/CT in the diagnosis and classification of bone metastases in prostate cancer.
引用
- Wang J, Li L, Feng T, et al. Bisphosphonate Bone Imaging Agent [68Ga]Ga-P15-041 for Evaluating Skeletal Metastases in Prostate Cancer: A Comparison With [68Ga]Ga-PSMA-11 PET/CT. Clin Nucl Med. 2025. PMID: 40320629. doi:10.1097/RLU.0000000000005883
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。